0.00Open0.00Pre Close0 Volume0 Open Interest22.50Strike Price0.00Turnover97.13%IV-28.94%PremiumDec 20, 2024Expiry Date5.05Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8286Delta0.0629Gamma3.26Leverage Ratio-0.0222Theta-0.0091Rho-2.70Eff Leverage0.0108Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet